Meghmani Organics Q4 FY26 Results: Revenue Down 9% YoY to ₹456.6 Cr
Meghmani Organics Limited reported Q4 FY26 revenue of ₹456.6 crore, down 9% YoY. Full-year FY26 consolidated revenue rose 5% to ₹2,174.0 crore. The company is proceeding with the amalgamation of KCL and MCNL with MOL, with shareholder meetings scheduled for June 6, 2026.
The quarterly results show a year-on-year decline, which could impact investor sentiment in the short term. However, the full-year consolidated results indicate growth, and the ongoing amalgamation could lead to future synergies.
The company reported a decline in revenue and EBITDA for the fourth quarter of FY26 compared to the previous year, primarily due to softer demand and rising input costs, although full-year consolidated figures showed growth.
Meghmani Organics Limited (MOL) has released its audited financial results for the fourth quarter and full year ended March 31, 2026. The company reported a revenue from operations of ₹456.6 crore for Q4 FY26, marking a 9% decrease year-on-year. EBITDA for the quarter stood at ₹26.2 crore, down from ₹64.6 crore in the corresponding quarter of the previous year.
The Crop Protection segment, which constitutes approximately 76% of the company's revenue in Q4 FY26, reported revenue of ₹348.6 crore and EBITDA of ₹31.3 crore, with an EBITDA margin of 9.0%. Production in this segment was 10,294 MT, up 6% year-on-year, with a capacity utilization of 74%.
The Pigments segment contributed about 24% to the revenue, with revenue at ₹108.0 crore and EBITDA at ₹3.2 crore, resulting in an EBITDA margin of 3.0%. Production in the Pigments segment decreased by 35% year-on-year to 2,495 MT, with a capacity utilization of 30%. The company cited softer demand amid macroeconomic uncertainties impacting export volumes and revenues, along with rising input costs, as reasons for the pressure on margins and profitability.
For the full fiscal year FY26, consolidated revenue from operations was ₹2,174.0 crore, a 5% increase year-on-year. Consolidated EBITDA stood at ₹176.4 crore, up 24% from FY25. The standalone P&L statement shows a full-year revenue of ₹2,091.8 crore, a 4% increase YoY, and EBITDA of ₹228.7 crore, a 27% increase YoY.
Meghmani Organics Limited is also progressing with its scheme of amalgamation, where Kilburn Chemicals Limited (KCL) and Meghmani Crop Nutrition Limited (MCNL) will be amalgamated with MOL. The NCLT has directed the convening of shareholder and creditor meetings, with remote e-voting scheduled from June 3-5, 2026, and the meeting on June 6, 2026. The rationale includes simplification of the group structure, operational and financial synergies, and stronger market positioning under a single brand.
What to do with a filing like this
Meghmani Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Meghmani Organics Limited. Read the original for the full detail.